Exact's colorectal cancer test in trial at Mayo Clinic
This article was originally published in Clinica
Executive Summary
The Mayo Clinic is to carry out a major prospective study of Exact Sciences' genomics-based colorectal cancer test with the support of a $4.9 million grant from the US National Cancer Institute. The test is based on analysis of DNA isolated from stool using the same sample processing technology as the PreGen-26 test launched at the end of May (see Clinica No 959, p 19).